Agios Pharmaceuticals Inc
AGIO28.020USD
-1.150-3.94%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.63BMarket Cap
LossP/E TTM
More Details of Agios Pharmaceuticals Inc Company
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Agios Pharmaceuticals Inc Info
Ticker SymbolAGIO
Company nameAgios Pharmaceuticals Inc
IPO dateJul 24, 2013
CEOGoff (Brian M)
Number of employees486
Security typeOrdinary Share
Fiscal year-endJul 24
Address88 Sidney Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02139
Phone16176498600
Websitehttps://www.agios.com/
Ticker SymbolAGIO
IPO dateJul 24, 2013
CEOGoff (Brian M)
Company Executives of Agios Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Brian M. Goff
Mr. Brian M. Goff
Chief Executive Officer, Director
Chief Executive Officer, Director
123.53K
+10.37%
Dr. Sarah Gheuens, M.D., Ph.D.
Dr. Sarah Gheuens, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
61.27K
--
Ms. Cecilia Jones
Ms. Cecilia Jones
Chief Financial Officer
Chief Financial Officer
33.87K
+12.72%
Ms. Tsveta Milanova
Ms. Tsveta Milanova
Chief Commercial Officer
Chief Commercial Officer
26.12K
+14.11%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
17.03K
+14.22%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
12.41K
+22.77%
Mr. Jeffrey D. (Jeff) Capello, CPA
Mr. Jeffrey D. (Jeff) Capello, CPA
Independent Director
Independent Director
6.07K
+207.34%
Mr. Krishnan Viswanadhan
Mr. Krishnan Viswanadhan
Chief Corporate Development and Strategy Officer
Chief Corporate Development and Strategy Officer
--
--
Dr. Jay Backstrom, M.D.
Dr. Jay Backstrom, M.D.
Director
Director
--
--
Mr. Christopher Taylor
Mr. Christopher Taylor
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Brian M. Goff
Mr. Brian M. Goff
Chief Executive Officer, Director
Chief Executive Officer, Director
123.53K
+10.37%
Dr. Sarah Gheuens, M.D., Ph.D.
Dr. Sarah Gheuens, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
61.27K
--
Ms. Cecilia Jones
Ms. Cecilia Jones
Chief Financial Officer
Chief Financial Officer
33.87K
+12.72%
Ms. Tsveta Milanova
Ms. Tsveta Milanova
Chief Commercial Officer
Chief Commercial Officer
26.12K
+14.11%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
17.03K
+14.22%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
12.41K
+22.77%
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
12.46M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Dec 7
Updated: Sun, Dec 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Farallon Capital Management, L.L.C.
9.91%
The Vanguard Group, Inc.
9.59%
BlackRock Institutional Trust Company, N.A.
6.83%
Erste Asset Management GmbH
4.74%
Paradigm BioCapital Advisors LP
4.58%
Other
64.35%
Shareholders
Shareholders
Proportion
Farallon Capital Management, L.L.C.
9.91%
The Vanguard Group, Inc.
9.59%
BlackRock Institutional Trust Company, N.A.
6.83%
Erste Asset Management GmbH
4.74%
Paradigm BioCapital Advisors LP
4.58%
Other
64.35%
Shareholder Types
Shareholders
Proportion
Investment Advisor
42.76%
Hedge Fund
30.41%
Investment Advisor/Hedge Fund
24.95%
Research Firm
3.33%
Private Equity
2.42%
Individual Investor
1.68%
Pension Fund
0.43%
Bank and Trust
0.36%
Insurance Company
0.03%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
470
64.77M
127.16%
+1.37K
2025Q3
480
64.83M
127.76%
-243.80K
2025Q2
465
63.41M
122.48%
+1.60M
2025Q1
466
62.14M
116.47%
-5.28M
2024Q4
447
61.85M
113.54%
+1.64M
2024Q3
437
60.91M
116.19%
-113.19K
2024Q2
428
60.47M
120.49%
-3.86M
2024Q1
403
64.08M
115.65%
-912.74K
2023Q4
385
62.06M
111.81%
+2.66M
2023Q3
390
61.07M
118.63%
-261.79K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Farallon Capital Management, L.L.C.
5.77M
9.93%
+67.00K
+1.18%
Jun 30, 2025
The Vanguard Group, Inc.
5.67M
9.76%
+75.90K
+1.36%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.17M
7.17%
-231.57K
-5.27%
Jun 30, 2025
Erste Asset Management GmbH
2.33M
4%
+96.59K
+4.33%
Jun 30, 2025
Paradigm BioCapital Advisors LP
2.83M
4.87%
+1.69M
+147.52%
Aug 21, 2025
Commodore Capital LP
2.33M
4%
+140.00K
+6.41%
Jun 30, 2025
State Street Investment Management (US)
1.95M
3.36%
-498.37K
-20.35%
Jun 30, 2025
Nomura Investment Management Business Trust
1.90M
3.27%
+50.05K
+2.70%
Jun 30, 2025
T. Rowe Price Associates, Inc.
2.22M
3.81%
-35.61K
-1.58%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
WisdomTree BioRevolution Fund
2.24%
Virtus LifeSci Biotech Products ETF
2.01%
Harbor Human Capital Factor US Small Cap ETF
1.06%
ALPS Medical Breakthroughs ETF
1.03%
State Street SPDR S&P Biotech ETF
0.72%
Invesco NASDAQ Future Gen 200 ETF
0.62%
WisdomTree US SmallCap Fund
0.61%
Global X Aging Population ETF
0.47%
Direxion Daily S&P Biotech Bull 3X Shares
0.44%
Amplify Etho Climate Leadership U.S. ETF
0.41%
View more
WisdomTree BioRevolution Fund
Proportion2.24%
Virtus LifeSci Biotech Products ETF
Proportion2.01%
Harbor Human Capital Factor US Small Cap ETF
Proportion1.06%
ALPS Medical Breakthroughs ETF
Proportion1.03%
State Street SPDR S&P Biotech ETF
Proportion0.72%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.62%
WisdomTree US SmallCap Fund
Proportion0.61%
Global X Aging Population ETF
Proportion0.47%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.44%
Amplify Etho Climate Leadership U.S. ETF
Proportion0.41%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Agios Pharmaceuticals Inc?
The top five shareholders of Agios Pharmaceuticals Inc are:
Farallon Capital Management, L.L.C. holds 5.77M shares, accounting for 9.93% of the total shares.
The Vanguard Group, Inc. holds 5.67M shares, accounting for 9.76% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.17M shares, accounting for 7.17% of the total shares.
Erste Asset Management GmbH holds 2.33M shares, accounting for 4.00% of the total shares.
Paradigm BioCapital Advisors LP holds 2.83M shares, accounting for 4.87% of the total shares.
Farallon Capital Management, L.L.C. holds 5.77M shares, accounting for 9.93% of the total shares.
The Vanguard Group, Inc. holds 5.67M shares, accounting for 9.76% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.17M shares, accounting for 7.17% of the total shares.
Erste Asset Management GmbH holds 2.33M shares, accounting for 4.00% of the total shares.
Paradigm BioCapital Advisors LP holds 2.83M shares, accounting for 4.87% of the total shares.
What are the top three shareholder types of Agios Pharmaceuticals Inc?
The top three shareholder types of Agios Pharmaceuticals Inc are:
Farallon Capital Management, L.L.C.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Agios Pharmaceuticals Inc (AGIO)?
As of 2025Q4, 470 institutions hold shares of Agios Pharmaceuticals Inc, with a combined market value of approximately 64.77M, accounting for 127.16% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.61%.
What is the biggest source of revenue for Agios Pharmaceuticals Inc?
In FY2025Q2, the -- business generated the highest revenue for Agios Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
